February 18, 2019
A Q&A with Grace Castillo-Soyao, founder and CEO of Self Care Catalysts; email@example.com Q: You are well known as a visionary in the field of Real World Experience-Evidence (RWEE). As the founder and CEO of Self Care Catalysts, headquartered in Toronto, how do you see RWEE evolving to favorably impact the field of oncology? A: I started Self Care Catalysts with some very basic… Read more »
September 25, 2018
Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC BookmarkEmma Shtivelman, PhD
Excerpt from OncLive:
“Treatment with apalutamide (Erleada) was not associated with a significant impact on health-related quality of life (HRQoL) in patients with high-risk nonmetastatic castration-resistant prostate cancer, according to patient-reported outcome (PRO) data from the phase III SPARTAN trial.
“In the study overall, patients treated with the addition of apalutamide to standard hormone therapy also had an improvement in metastasis-free survival (MFS) and longer time to symptomatic progression compared with those who were treated with placebo.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
September 4, 2018
A Q&A with Jared Adams MD, PhD, Chief Science Officer at Self Care Catalysts; firstname.lastname@example.org Q: Patient-reported outcomes (PROs) are health care outcomes, such as symptoms or quality of life, reported directly by a patient. In recent years, PROs have emerged as a potentially powerful new way to understand cancer outcomes. Could PROs lead to the next breakthrough in our understanding of cancer? A: When biochemist and… Read more »